Literature DB >> 14692718

Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.

M Heim1, M Sharifi, R A Hilger, M E Scheulen, S Seeber, D Strumberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14692718     DOI： 10.5414/cpp41616

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  10 in total

Review 1.  Current and future management strategies for relapsed or progressive hepatoblastoma.

Authors:  Rajkumar Venkatramani; Wayne L Furman; Joerg Fuchs; Steven W Warmann; Marcio H Malogolowkin
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

2.  Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

Authors:  Stephen K Williamson; James Moon; Chao H Huang; Perry P Guaglianone; Michael LeBlanc; Gregory T Wolf; Susan G Urba
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

3.  Converting biology into clinical benefit: lessons learned from BRAF inhibitors.

Authors:  Jennifer McQuade; Michael A Davies
Journal:  Melanoma Manag       Date:  2015

Review 4.  Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

Authors:  Yuanxiang Wang; Christine E Kaiser; Brendan Frett; Hong-Yu Li
Journal:  J Med Chem       Date:  2013-04-23       Impact factor: 7.446

5.  Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.

Authors:  Minny Bhatty; Shumei Kato; Sarina A Piha-Paul; Aung Naing; Vivek Subbiah; Helen J Huang; Daniel D Karp; Apostolia M Tsimberidou; Ralph G Zinner; Wen-Jen Hwu; Milind Javle; Sapna P Patel; Mimi I Hu; Gauri R Varadhachary; Anthony P Conley; Nishma M Ramzanali; Veronica R Holley; Razelle Kurzrock; Funda Meric-Bernstam; Young Kwang Chae; Kevin B Kim; Gerald S Falchook; Filip Janku
Journal:  Cancer       Date:  2018-11-01       Impact factor: 6.860

Review 6.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

Authors:  William H Chappell; Linda S Steelman; Jacquelyn M Long; Ruth C Kempf; Stephen L Abrams; Richard A Franklin; Jörg Bäsecke; Franca Stivala; Marco Donia; Paolo Fagone; Graziella Malaponte; Maria C Mazzarino; Ferdinando Nicoletti; Massimo Libra; Danijela Maksimovic-Ivanic; Sanja Mijatovic; Giuseppe Montalto; Melchiorre Cervello; Piotr Laidler; Michele Milella; Agostino Tafuri; Antonio Bonati; Camilla Evangelisti; Lucio Cocco; Alberto M Martelli; James A McCubrey
Journal:  Oncotarget       Date:  2011-03

7.  Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.

Authors:  Su Jin Lee; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Won Ki Kang; Jongtae Lee; Dong-Seok Yim; Ho Yeong Lim
Journal:  Invest New Drugs       Date:  2011-06-22       Impact factor: 3.651

Review 8.  Application of computational methods for anticancer drug discovery, design, and optimization.

Authors:  Diego Prada-Gracia; Sara Huerta-Yépez; Liliana M Moreno-Vargas
Journal:  Bol Med Hosp Infant Mex       Date:  2016-11-30

9.  Rational Design of Novel Inhibitors of α-Glucosidase: An Application of Quantitative Structure Activity Relationship and Structure-Based Virtual Screening.

Authors:  Sobia Ahsan Halim; Sumaira Jabeen; Ajmal Khan; Ahmed Al-Harrasi
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-19

10.  Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

Authors:  Shailender Bhatia; James Moon; Kim A Margolin; Jeffrey S Weber; Christopher D Lao; Megan Othus; Ana M Aparicio; Antoni Ribas; Vernon K Sondak
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.